Matches in Nanopublications for { ?s ?p "Dabrafenib mesylate is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. FDA approved on May 29, 2013."@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
Nanopublications LDF server
